Executive Team
Cancer Advances is a company led by an experienced team with more than 200 years of combined industry experience.
Daniel Pharand, Chief Executive Officer and Chief Financial Officer
Daniel Pharand, C.A. is a Chartered accountant with over 25 years of experience in the pharmaceutical, biotech and life sciences industries with a proven track record. He also currently serves as a Principal of Cato BioVentures and as Chief Financial Officer of Cato Research, as well as Chief Strategic Officer and Chief Financial Officer of Cancer Advances. Mr. Pharand was the Chief Financial Officer of Pharmacia Canada and of Pharmacia KK (Japan). He subsequently became an entrepreneur with a successful Canadian distribution company of innovative pedicular screws systems in orthopaedic therapies. Mr Pharand later was involved in the Biotech Venture with Innovatech Grand Montreal over his 5 years as Portfolio Manager. Mr. Pharand has also acted as a director and has served on various boards for more than 30 publicly traded or life sciences corporations, including Corautus Genetics Inc. (NASDAQ : VEGF), Bio 1 Inc. (now TSX-V: ARU), LAB International Inc. (TSX : LAB) and Mistral Pharma Inc. (TSX-V: MPI).
Lynda Sutton, President
Lynda Sutton, B.S. currently serves as the Chief Operating Officer and Chief Regulatory Officer for Cato Research, and President for Cancer Advances. Ms. Sutton has 25 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics. She has coordinated activities in various disciplines and has been involved in the development of new clinical entities, has overseen the preparation of FDA pre-meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied. She has served as the primary regulatory contact for more than 100 Biotech and pharmaceutical companies over the last 19 years. In addition, Ms. Sutton has cofounded several small biotechnology companies and serves as a member of the board of directors for several companies. She has expertise in the development of biological products, with emphasis on gene therapy and blood products, and in the development of oncological, anti-infective, and neuropharmacological products.
Allen Cato, Chief Medical Officer
Allen Cato, M.D., Ph.D. cofounded Cato Research and Cato BioVentures and has more than 40 years of experience in clinical study design, regulatory interactions, adverse drug reactions, and clinical research and new drug development. He has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato has published more than 100 papers, principally in the field of clinical pharmaceutical research, and he participates as a member of the board of directors for several pharmaceutical and biotechnology companies.
